BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342 [PMID: 35979179 DOI: 10.4330/wjc.v14.i6.329]
URL: https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm
Number Citing Articles
1
Antonina Kedyk, Oleksandr Kutsyn. Metabolic effects of empagliflozineDiabetes Obesity Metabolic Syndrome 2022; (5): 38 doi: 10.57105/2415-7252-2022-5-04
2
Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu, Jianpeng Yuan. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patientsFrontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1028486
3
Aftab Ahmad, Hani Sabbour. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studiesCardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02192-4
4
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, Ghanshyam Das Gupta, Surendra H. Bodakhe, Amrita Singh. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical EvidenceCurrent Diabetes Reviews 2024; 20(6) doi: 10.2174/1573399820666230809152148
5
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysiseClinicalMedicine 2023; 64: 102181 doi: 10.1016/j.eclinm.2023.102181